Breaking News Instant updates and real-time market news.

SBUX

Starbucks

$64.18

(0.00%)

, GM

General Motors

$34.73

(0.00%)

09:40
01/11/19
01/11
09:40
01/11/19
09:40

Unusually active option classes on open January 11th

Unusual total active option classes on open include: Starbucks (SBUX), General Motors (GM), Tilray (TLRY), Caesars (CZR), Materials Sector SPDR ETF (XLB), Canopy Growth (CGC), Netflix (NFLX), Amarin (AMRN), Bed Bath & Beyond (BBBY), and SPDR S&P Regional Banking (KRE).

SBUX

Starbucks

$64.18

(0.00%)

GM

General Motors

$34.73

(0.00%)

TLRY

Tilray

$80.75

(0.00%)

CZR

Caesars

$7.99

(0.00%)

XLB

S&P Select Materials SPDR

$52.48

(0.00%)

CGC

Canopy Growth

$37.52

(0.00%)

NFLX

Netflix

$324.77

(0.00%)

AMRN

Amarin

$18.32

(0.00%)

BBBY

Bed Bath & Beyond

$14.30

(0.00%)

KRE

SPDR S&P Regional Banking ETF

$49.83

(0.00%)

  • 11

    Jan

  • 14

    Jan

  • 15

    Jan

  • 15

    Jan

  • 24

    Jan

  • 06

    Feb

  • 18

    Feb

SBUX Starbucks
$64.18

(0.00%)

01/11/19
GSCO
01/11/19
DOWNGRADE
Target $68
GSCO
Neutral
Starbucks downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Karen Holthouse downgraded Starbucks to Neutral and lowered her price target for the shares to $68 from $75. The coffee giant closed yesterday up 31c to $64.19. The analyst remains "reasonably confident" that Starbucks' initiatives to drive digital engagement can lead to a "more stable" 3%-4% comp trajectory in the U.S. over the next few years. However, its valuation has "rapidly re-rated" to reflect this, and gift cards and digital trends could be points of caution in fiscal Q1, Holthouse tells investors in a research note. Further, she has "incremental concerns" regarding the China macro environment and the company's comp trajectory in that region. Other consumer companies, like Apple (AAPL) and McDonald's (MCD), have noted weakness in China, the analyst points out. Holthouse this morning also upgraded Texas Roadhouse (TXRH) to Buy from Neutral and downgraded Yum! Brands (YUM) to Sell from Neutral.
12/19/18
JPMS
12/19/18
NO CHANGE
Target $70
JPMS
Overweight
JPMorgan likes shares of Starbucks at current levels
JPMorgan analyst John Ivankoe says he likes shares of Starbucks at current levels after taking a group of investors to the company's Seattle headquarters. Improved visibility into U.S. comp improvement, driven by various sales-driving initiatives along with 6%-7% global unit growth, will allow Starbucks to sustain a premium multiple, Ivankoe tells investors in a research note. He keeps an Overweight rating on the shares with a $70 price target.
01/11/19
BMOC
01/11/19
NO CHANGE
Target $60
BMOC
Market Perform
Starbucks price target lowered to $60 from $63 at BMO Capital
BMO Capital analyst Andrew Strelzik lowered his price target on Starbucks to $60 and kept his Market Perform rating, saying the company's "valuation resiliency" appears to be "disconnected" from changes to the fundamentals. The analyst notes that in spite of trading at "multiyear high relative valuation metrics", Starbucks is facing slower growth and a less solid outlook for its China market. Strelzik adds that although there may not be a near term downside catalyst, the risk-reward on Starbucks appears to be tilted to the downside.
12/14/18
BMOC
12/14/18
NO CHANGE
Target $63
BMOC
Market Perform
Starbucks price target raised to $63 from $58 at BMO Capital
BMO Capital analyst Andrew Strelzik raised his price target on Starbucks to $63 after its Investor Day presentation. The analyst notes that the company's "lowering of long-term algorithm may have caught the market by surprise", but his takeaway from the event is "incrementally positive" based on the CEO commentary around comps estimates and slowing net store openings reducing "cannibalization concerns". Strelzik keeps his Market Perform rating on Starbucks however, stating that its valuation is "too expensive" to get more constructive.
GM General Motors
$34.73

(0.00%)

01/07/19
01/07/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Outperform from Market Perform at BMO Capital with analyst Richard Carlson citing a "brighter spotlight" being placed on the GM Cruise model in 2019 leading to more appropriate value being priced into the shares. 2. Alphabet (GOOG, GOOGL), Adobe (ADBE), and Salesforce (CRM) were upgraded to Buy from Hold at Pivotal Research. 3. Citi (C) upgraded to Outperform from Neutral at Macquarie with analyst David Konrad saying despite macro uncertainties, he sees Citi's stock as compelling due to his expectations for improving performance, continued operating leverage and credit risk concerns that he views as overdone. 4. Micron (MU) upgraded to Outperform from Market Perform at BMO Capital with analyst Ambrish Srivastava citing valuation. 5. Dillard's (DDS) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss saying he sees a more balanced risk/reward with the stock underperforming the over the past few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/19
BMOC
01/07/19
UPGRADE
Target $41
BMOC
Outperform
General Motors upgraded to Outperform at BMO Capital on Cruise potential
As reported earlier, BMO Capital analyst Richard Carlson upgraded General Motors to Outperform from Market Perform and also raised his price target to $41 from $38. The analyst cites a "brighter spotlight" being placed on the GM Cruise model in 2019 leading to more appropriate value being priced into the shares. Carlson also believes that General Motors' restructuring measures will yield improved profitability and higher free cash flows while also generating "cyclical resilience" for the stock that should generate a higher multiple.
01/11/19
BUCK
01/11/19
NO CHANGE
Target $34
BUCK
Neutral
General Motors may guide down at today's investor event, says Buckingham
Buckingham analyst Joseph Amaturo kept his Neutral rating and $34 price target on General Motors, saying the company's capital markets event today may produce "modest pressure" on its stock price with the release of lower financial guidance. The analyst adds that while some of this expectation is reflected in the automaker's current valuation of 6.2-times expected 2019 earnings, he expects the near term investor sentiment to remain cautious, particularly given the company's "very large presence" in the China market.
01/07/19
BMOC
01/07/19
UPGRADE
BMOC
Outperform
General Motors upgraded to Outperform from Market Perform at BMO Capital
TLRY Tilray
$80.75

(0.00%)

12/18/18
COWN
12/18/18
NO CHANGE
COWN
Outperform
Cowen sees Sandoz deal as reinforcing Tilray's competitive positioning
Tilray's (TLRY) expanded global partnership with Novartis (NVS) division Sandoz can not only help expand its reach with pharmacists, physicians and distributors, it can also help Tilray capture early share in new medical cannabis markets as they come online, Cowen analyst Vivien Azer tells investors in a research note. Further, the analyst believes the partnership also helps legitimize cannabis in international markets, which could help influence countries considering medical cannabis legalization. Azer estimates international will represent 15% of Tilray's revenue in fiscal 2020 and 22% in fiscal 2021. Not only does the deal allow Tilray to expand geographic reach, but also to grow at scale, says Azer. And most notably, the Sandoz deal reinforces Tilray's competitive positioning, adds the analyst, who keeps an Outperform rating on the shares with a $150 price target. The stock in morning trading is up 9%, or $5.98, to $71.87.
01/09/19
PIPR
01/09/19
INITIATION
PIPR
Overweight
Piper Jaffray rolls out bullish research coverage on Canopy Growth, Tilray
Piper Jaffray analyst Michael Lavery initiated coverage of Canopy Growth (CGC) and Tilray (TLRY) with Overweight ratings and price targets of $40 and $90, respectively. The analyst believes the global Cannabis market has the potential to reach $250B-$500B over the long term and $15B-$50B in the near term. The industry's long-term growth opportunities are significant, both from transitioning illicit trade to legal sales and from transitioning sales in health and wellness categories to cannabidiol-infused products, Lavery tells investors in a research note. The analyst expects recreational use to source from illicit trade and alcohol, medical use to source from other medical treatments, and non-psychoactive CBD-infused cannabis products to source users from food, beverage, and personal care categories. Over 25 countries have legal marijuana use today, he points out. Lavery believes federal legalization in the U.S. could potentially come in the next five years. Further, the analyst expects capital flow into the sector will likely continue.
01/09/19
PIPR
01/09/19
INITIATION
Target $90
PIPR
Overweight
Tilray initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery initiated coverage of Tilray with an Overweight rating and $90 price target. The analyst expects "strong" industry growth long-term, and believes Tilray is well positioned to be one of several likely winners given its relationships in medical, in the U.S., and in beverages. Lavery consider the company's initial public offering lock-up expiry to be a near-term risk, especially with 77% insider ownership, but his 12-month Overweight view is based on its fundamental outlook. He pegs Tilray's market opportunity at $15B-$50B in the near-term, and potentially $250B-$500B over the longer term.
11/14/18
BNCH
11/14/18
NO CHANGE
Target $200
BNCH
Buy
Tilray reported 'strong' Q3 sales without recreational cannabis, says Benchmark
Benchmark analyst Mike Hickey said Tilray reported "strong" Q3 sales even though the company did not recognize sales from recreational cannabis use in the quarter. Recreational use experienced a slow start, primarily due to the timing of licenses, distribution and retail infrastructure, as expected, said Hickey, who adds that there "appears to be exceedingly strong demand" from Canadians. He has raised his Q4 sales forecast based on increased production and presumed ongoing strong consumer demand and keeps a Buy rating on Tilray with a $200 price target.
CZR Caesars
$7.99

(0.00%)

11/02/18
JEFF
11/02/18
NO CHANGE
Target $11
JEFF
Hold
Jefferies lowers Caesars target to $11 after 'softness' in Q3
Jefferies analyst David Katz views the "softness" in Caesars Entertainment's Q3 results as less consequential than the announcements of a leadership change and the decision to revisit the guidance process going forward, which he believes are "undoubtedly constructive in the longer term." Nonetheless, the analyst lowered his price target for Caesars to $11 from $12 and keeps a Hold rating on the name. The positive merits of the "increasingly clearer operating story" are tempered by the capital structure and allocation, Katz tells investors in a post-earnings research note titled "Change Can Be a Good Thing."
01/07/19
DBAB
01/07/19
NO CHANGE
DBAB
Wynn, Caesars best large-cap Gaming stocks for 2019, says Deutsche Bank
Deutsche Bank analyst Carlo Santarelli says Wynn Resorts (WYNN) and Caesars Entertainment (CZR) are the best ways to play the large-cap Gaming space in 2019. Given current valuations and fundamental expectations "that seemingly accompany those valuations," the analyst is constructive on the larger-cap Gaming names and sees a bias to the upside in the stocks.
11/15/18
BERN
11/15/18
INITIATION
Target $9.1
BERN
Market Perform
Caesars initiated with a Market Perform at Bernstein
Bernstein analyst Vitaly Umansky started Caesars with a Market Perform rating and $9.10 price target. The analyst notes that over the last five years, gaming stocks have gone through periods of significant underperformance, followed by significant outperformance. The last six months have been exceptionally difficult for gaming stocks as Macau growth has begun to decelerate following nearly two years of strong growth and Las Vegas has seen unexpected near-term softness, he contends. However, Umansky argues that the gaming space has shown that if investors pick the right market, the right company, at the right time, outsized returns are possible.
01/02/19
UBSW
01/02/19
UPGRADE
Target $7
UBSW
Neutral
Caesars upgraded to Neutral from Sell at UBS
UBS analyst Robin Farley upgraded Caesars Entertainment to Neutral while lowering her price target for the shares to $7 from $9. The analyst says her "bearish thesis" is now priced in with the stock down 33% over the past three months. Farley believes her below-consensus view on the Las Vegas market is more factored into the stock at these levels.
XLB S&P Select Materials SPDR
$52.48

(0.00%)

CGC Canopy Growth
$37.52

(0.00%)

01/10/19
JEFF
01/10/19
NO CHANGE
Target $258
JEFF
Buy
Constellation risk/reward remains favorable after selloff, says Jefferies
Jefferies analyst Kevin Grundy lowered his estimates for Constellation Brands following yesterday's fiscal 2019 guidance reduction but he believes the stock's risk/reward remains favorable. The analyst lowered his price target for the shares to $258 from $269 and keeps a Buy rating on Constellation. The company's beer business remains healthy and its investment in Canopy Growth (CGC) is now a free call option, Grundy tells investors in a research note.
01/10/19
GSCO
01/10/19
UPGRADE
Target $211
GSCO
Buy
Constellation Brands upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Judy Hong upgraded Constellation Brands (STZ) to Buy while lowering her price target for the shares to $211 from $243. The stock closed yesterday down 12.5%, or $21.57, to $150.94 post the company's Q3 earnings report. Constellation is down over 30% in the past 12 months, mostly driven by multiple contraction, Hong tells investors in a research note. The analyst reduced her estimates to reflect a "softer outlook" but sees a "compelling" risk/reward at current share levels. Her model yields a $195 per share value for the core business excluding Canopy Growth (CGC) and a consolidated price target of $211, pointing to 40% upside. Beer sales growth should remain healthy and beer margins should improve in fiscal 2020 as cost headwinds are lapped, Hong contends. Further, she believes Constellation shares could outperform even if investors assign zero value to its investment in Canopy.
01/10/19
RHCO
01/10/19
NO CHANGE
Target $165
RHCO
Hold
Constellation Brands price target lowered to $165 from $180 at SunTrust
SunTrust analyst William Chappell lowered his price target on Constellation Brands (STZ) to $165 and kept his Hold rating on the stock. The analyst cites the company's reported expectations of declining wine and spirits sales, adding that the latest $4B investment in Canopy Growth (CGC) will be the "cloud" hanging over the stock for the next few quarters because of the uncertainty related to its potential growth.
01/10/19
WELS
01/10/19
NO CHANGE
Target $235
WELS
Market Perform
Constellation Brands price target lowered to $235 from $260 at Wells Fargo
Wells Fargo analyst Bonnie Herzog lowered her price target for Constellation Brands (STZ) to $235 from $260 following "disappointing' Q3 results and FY19 guide down. The continues to view the stock as best-in-class with huge potential upside from its cannabis investment and therefore believes the sharp selloff in the shares is "way overdone!" However, Constellation Brands' miss on beer depletions, guide down on FY19 beer OI margin, pressure on its wine biz and lack of visibility on the impact of its Canopy Growth (CGC) investment on earnings will likely "keep the bears growling near-term." Herzog reiterates an Outperform rating on Constellation Brands' shares.
NFLX Netflix
$324.77

(0.00%)

01/11/19
MSCO
01/11/19
NO CHANGE
Target $430
MSCO
Overweight
Netflix price target lowered to $430 from $475 at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne lowered his price target on Netflix (NFLX) shares to $430 from $475 as he factored in his "modestly lower" view on long-term margins and the broader de-rating of the stock in the market. While he currently forecasts 27M global paid net adds in 2019, Swinburne has tempered his 2019 ARPU growth view, noting that Netflix has not implemented broad price increases as of yet. He still believes Netflix's long-term pricing power remains intact, though he is now taking a more conservative approach to ARPU growth in emerging markets longer term. Swinburne keeps an Overweight rating on Netflix, citing the nearly $500B global TV market it has the potential to address and his view that while many traditional TV studio owners, like Disney (DIS), will pivot to streaming, most likely will not.
01/11/19
RAJA
01/11/19
UPGRADE
Target $450
RAJA
Strong Buy
Raymond James upgrades Netflix to Strong Buy, sees material profitability ahead
As previously reported, Raymond James analyst Justin Patterson upgraded Netflix to Strong Buy from Outperform and raised his price target on the stock to $450 from $435. Netflix is approaching a profit inflection, as the company's front-loaded headcount investments will be leveraged and lead to an operating margin inflection, contends Patterson. His survey work shows Netflix's traction in film is helping it gain share against linear TV and he sees meaningful potential for Netflix to succeed in film, which Patterson believes should aid subscriber growth, retention and pricing power, he added. Last night, UBS analyst Eric Sheridan also upgraded Netflix to Buy from Neutral and raised his price target for the shares to $410 from $400.
01/11/19
RAJA
01/11/19
UPGRADE
RAJA
Strong Buy
Netflix upgraded to Strong Buy from Outperform at Raymond James
01/11/19
UBSW
01/11/19
UPGRADE
Target $410
UBSW
Buy
UBS is 'taking the blindfold off,' upgrades Netflix shares to Buy
UBS analyst Eric Sheridan last night upgraded Netflix to Buy from Neutral and raised his price target for the shares to $410 from $400. The streaming giant closed yesterday up $4.70 to $324.66. After six months of stock underperformance as key debates emerged about competition, margins and free cash flow, the debates are better understood by investors and reflected in the current stock price, Sheridan tells investors in a research note partially titled "Taking The Blindfold Off." The analyst sees share upside over the near-to-medium term to subscriber growth. Current subscriber metrics such as growth, churn, spend and consumption are tracking inline to better than management's Q4 guidance and commentary, Sheridan says, citing his firm's Evidence Lab.
AMRN Amarin
$18.32

(0.00%)

01/08/19
SBSH
01/08/19
NO CHANGE
Target $20
SBSH
Buy
Amarin price target lowered to $20 from $28 at Citi
Citi analyst Joel Beatty lowered his price target for Amarin to $20 after the company's 2019 revenue guidance came in lower than he expected. The analyst, however, continues to view Vascepa as an "attractive and differentiated cardiovascular risk reduction therapy." His peak sales estimate is now $2.5B, down from $3.0B previously.
01/07/19
RHCO
01/07/19
NO CHANGE
Target $15
RHCO
Buy
Amarin price target lowered to $15 from $30 at SunTrust
SunTrust analyst John Boris lowered his price target on Amarin after the company guided its FY19 revenue outlook well below consensus and offered more details timing of Vascepa sNDA filing. The analyst contends that the company needs to employ a larger sales force to "realize Vascepa full potential" beyond the 400 reps currently and also lowers his FY19 EPS view to (23c) from 18c to reflect Amarin's expectations of lower sales and higher SG&A costs. Longer term, Boris keeps his Buy rating on Amarin, noting that Vascepa could have a "significant commercial upside" if it can secure a label for reducing cardiovascular risk.
12/20/18
JEFF
12/20/18
NO CHANGE
Target $30
JEFF
Buy
Amarin shares will bounce back on 2019 catalysts, says Jefferies
After hosting meetings with management, Jefferies analyst Michael Yee says Amarin represents one of the few "de-risked" standalone blockbuster drugs in the smid-cap Biotech space. Following the stock's pullback from of $23 to $15, Amarin will "bounce and go back up," predicts the analyst. He sees 2019 catalysts from "scripts and sales ramp to FDA approval." Further, a potential takeout is a "wildcard," writes Yee in a note titled "The Big Fish In A Big Pond? Update from Mgmt Meetings..." The analyst keeps a Buy rating on Amarin with a $30 price target.
01/07/19
JEFF
01/07/19
NO CHANGE
Target $30
JEFF
Buy
Jefferies keeps $30 target on Amarin, says guidance conservative
Amarin Friday night reported "strong" Q4 Vascepa results, although stock is trading lower perhaps due to conservative guidance, Jefferies analyst Michael Yee tells investors in a research note. The analyst views the news "as a positive sign of what's been going on recently." Amarin does not even have a label expansion yet and it has been only two months since the mid-November data presentation, Yee writes. He expects trends to continue to grow monthly throughout the year, even before Amarin receives a formal label expansion. While the stock may be down today, "things look strong fundamentally," Yee contends. He views the company's sales guidance as conservative and keeps a Buy rating on Amarin with a $30 price target.
BBBY Bed Bath & Beyond
$14.30

(0.00%)

10/01/18
ARGS
10/01/18
DOWNGRADE
ARGS
Hold
Bed Bath & Beyond downgraded to Hold from Buy at Argus
Argus analyst Christopher Graja downgraded Bed Bath & Beyond to Hold after lowering his earnings estimates to reflect on ongoing gross margin pressure, declines in store traffic and spending on systems and consultants. The disappointing Q2 results amid a very strong retail environment is a concern, Graja tells investors in a research note. The analyst is no longer confident in management's ability to focus on the company's long-term objectives.
01/02/19
LOOP
01/02/19
NO CHANGE
Target $12
LOOP
Hold
Loop Capital says Bed Bath Beyond, Amazon price gap widens to historical levels
Loop Capital analyst Anthony Chukumba kept his Hold rating and $12 price target on Bed Bath & Beyond (BBBY), saying his periodic pricing study demonstrated that the gap between the company and Amazon.com (AMZN) has widened back to its "historical level". The analyst sees this as a likely negative for the former, but also notes that that discounting has been a challenge in maintaining its gross margins. Chukumba maintains his forecasts on Bed Bath results ahead of next week's earnings, adding that while its stock trades at a discount to historical average levels, the 6.5-times expected forward earnings multiple is "in line" with other "secularly challenged specialty hardlines retailers."
11/08/18
SBSH
11/08/18
NO CHANGE
Target $13
SBSH
Sell
Bed Bath & Beyond activist probability low, 'screens well' for LBO, says Citi
Citi analyst Kate McShane reiterated a Sell rating on Bed Bath & Beyond shares, noting that the company has faced and continues to face significant challenges despite having enacted a number of changes in recent years. She views activist involvement or an LBO as a low probability given the number of challenges faced, but added that Bed Bath "has always screened well" as an LBO candidate. In a leveraged buyout scenario, the company could cut the dividend, shut down stores and create a smaller store format as a private company, McShane said.
10/02/18
LOOP
10/02/18
NO CHANGE
Target $15
LOOP
Hold
Bed Bath & Beyond pricing gap with Amazon narrowed in August, says Loop Capital
Loop Capital analyst Anthony Chukumba kept his Hold rating and $15 price target on Bed Bath & Beyond (BBBY), saying his channel checks indicate a further narrowing of the pricing gap with Amazon (AMZN). The analyst notes the gap in August has shrunk to 13.6% on average vs. 16.9% in July, but also warns that given its position as the "most dynamic retailer" in the U.S. in terms of pricing, Amazon can "quickly and easily lower prices if top-line growth underperforms".
KRE SPDR S&P Regional Banking ETF
$49.83

(0.00%)

TODAY'S FREE FLY STORIES

PTC

PTC

$84.73

-1.14 (-1.33%)

20:28
01/23/19
01/23
20:28
01/23/19
20:28
Recommendations
PTC analyst commentary  »

PTC price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

UNP

Union Pacific

$154.20

-0.8 (-0.52%)

, BMY

Bristol-Myers

$49.92

0.21 (0.42%)

20:25
01/23/19
01/23
20:25
01/23/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

UNP

Union Pacific

$154.20

-0.8 (-0.52%)

BMY

Bristol-Myers

$49.92

0.21 (0.42%)

LUV

Southwest

$50.97

0.425 (0.84%)

MKC

McCormick

$139.03

0.31 (0.22%)

FCX

Freeport McMoRan

$12.30

-0.08 (-0.65%)

GWW

Grainger

$297.12

-3.29 (-1.10%)

AAL

American Airlines

$31.57

-1.18 (-3.60%)

HBAN

Huntington Bancshares

$13.56

0.05 (0.37%)

TXT

Textron

$49.19

0.76 (1.57%)

JBLU

JetBlue

$17.23

-0.13 (-0.75%)

AEP

American Electric

$77.00

0.65 (0.85%)

TAL

TAL Education

$31.21

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 28

    Jan

  • 07

    Feb

  • 18

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

ADTN

Adtran

$12.25

0.49 (4.17%)

20:14
01/23/19
01/23
20:14
01/23/19
20:14
Earnings
Adtran reports Q4 adjusted EPS (12c), consensus (3c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

MSFT

Microsoft

$106.77

0.91 (0.86%)

, GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

20:10
01/23/19
01/23
20:10
01/23/19
20:10
Periodicals
China blocks Microsoft's Bing search engine, FT reports »

China regulators have…

MSFT

Microsoft

$106.77

0.91 (0.86%)

GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

BIDU

Baidu

$163.22

2.81 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 30

    Jan

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

EBAY

eBay

$32.62

-0.3 (-0.91%)

20:03
01/23/19
01/23
20:03
01/23/19
20:03
Recommendations
eBay analyst commentary  »

eBay should consider…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

CLR

Continental Resources

$45.30

-0.27 (-0.59%)

20:00
01/23/19
01/23
20:00
01/23/19
20:00
Conference/Events
Continental Resources to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

APY

Apergy

$33.20

-0.35 (-1.04%)

19:55
01/23/19
01/23
19:55
01/23/19
19:55
Initiation
Apergy initiated  »

Apergy initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

  • 19

    Feb

AMZN

Amazon.com

$1,641.50

7.35 (0.45%)

19:15
01/23/19
01/23
19:15
01/23/19
19:15
Hot Stocks
AWS unveils Amazon WorkLink solution »

Amazon Web Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 28

    Jan

  • 31

    Jan

  • 04

    Feb

  • 20

    Feb

  • 03

    Mar

SMBK

SmartFinancial

$18.35

0.21 (1.16%)

19:08
01/23/19
01/23
19:08
01/23/19
19:08
Earnings
SmartFinancial reports Q4 operating EPS 43c, consensus 37c »

SmartFinancial Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

MLRYY

Mail.Ru Group

$0.00

(0.00%)

19:05
01/23/19
01/23
19:05
01/23/19
19:05
Downgrade
Mail.Ru Group rating change  »

Mail.Ru Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$152.03

-0.1 (-0.07%)

18:58
01/23/19
01/23
18:58
01/23/19
18:58
Periodicals
Zhongnan Group to buy Alibaba-backed EasyHome for CNY38B, Bloomberg says »

Alibaba owns a 15% stake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 03

    Mar

  • 04

    Mar

JPM

JPMorgan

$102.72

-0.23 (-0.22%)

18:55
01/23/19
01/23
18:55
01/23/19
18:55
Periodicals
JPMorgan exec says private bank expands ops in Mexico, Reuters says »

JPMorgan's private…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SLM

Sallie Mae

$9.49

0.1 (1.07%)

, XLNX

Xilinx

$89.55

-0.89 (-0.98%)

18:53
01/23/19
01/23
18:53
01/23/19
18:53
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: SLM…

SLM

Sallie Mae

$9.49

0.1 (1.07%)

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

AZPN

Aspen Technology

$89.08

0.22 (0.25%)

LRCX

Lam Research

$139.24

-0.58 (-0.41%)

URI

United Rentals

$115.98

-2.21 (-1.87%)

TER

Teradyne

$31.93

0.13 (0.41%)

VAR

Varian Medical

$126.83

1.57 (1.25%)

CP

Canadian Pacific

$195.71

0.02 (0.01%)

TXN

Texas Instruments

$95.49

-1.05 (-1.09%)

F

Ford

$8.34

-0.17 (-2.00%)

BGG

Briggs & Stratton

$13.73

-0.46 (-3.24%)

PTC

PTC

$84.73

-1.14 (-1.33%)

CTXS

Citrix

$108.64

0.4 (0.37%)

LVS

Las Vegas Sands

$57.25

0.26 (0.46%)

FFIV

F5 Networks

$159.65

2.5 (1.59%)

CCI

Crown Castle

$110.28

1.13 (1.04%)

NCNA

NuCana

$14.37

-0.38 (-2.58%)

ADXS

Advaxis

$0.32

-0.0283 (-8.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 28

    Jan

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 11

    Feb

  • 14

    Feb

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

  • 25

    Apr

  • 28

    May

  • 24

    Jul

  • 23

    Oct

  • 25

    Jan

FB

Facebook

$144.35

-3.45 (-2.33%)

18:41
01/23/19
01/23
18:41
01/23/19
18:41
Periodicals
Advocacy groups pushing FTC to force Facebook breakup, WSJ says »

Multiple advocacy groups…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

, GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

18:38
01/23/19
01/23
18:38
01/23/19
18:38
Periodicals
Devs say Google's Chrome proposal threatens ad blockers, Bloomberg says »

Developers are…

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

FCPT

Four Corners Property Trust

$26.58

-0.09 (-0.34%)

, BLMN

Bloomin' Brands

$19.15

0.08 (0.42%)

18:36
01/23/19
01/23
18:36
01/23/19
18:36
Recommendations
Four Corners Property Trust, Bloomin' Brands analyst commentary  »

Four Corners Property…

FCPT

Four Corners Property Trust

$26.58

-0.09 (-0.34%)

BLMN

Bloomin' Brands

$19.15

0.08 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

BAC

Bank of America

$28.91

-0.18 (-0.62%)

18:11
01/23/19
01/23
18:11
01/23/19
18:11
Periodicals
Bank of America appoints Mike Joo as investment operating chief, Reuters says »

Head of global rates and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 03

    Mar

F

Ford

$8.34

-0.17 (-2.00%)

18:08
01/23/19
01/23
18:08
01/23/19
18:08
Hot Stocks
Ford says Russian alliance 'under review' »

Says won't have to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

F

Ford

$8.34

-0.17 (-2.00%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CHMG

Chemung Financial

$41.99

-0.11 (-0.26%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Earnings
Chemung Financial reports Q4 EPS $1.18, consensus $1.04 »

Reports Q4 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.34

-0.17 (-2.00%)

18:03
01/23/19
01/23
18:03
01/23/19
18:03
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 2019 will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

F

Ford

$8.34

-0.17 (-2.00%)

18:01
01/23/19
01/23
18:01
01/23/19
18:01
Hot Stocks
Ford says 2018 auto EBIT benefited from improvement of market factors »

Says auto EBIT in 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

HSIC

Henry Schein

$76.92

-0.45 (-0.58%)

17:56
01/23/19
01/23
17:56
01/23/19
17:56
Hot Stocks
Henry Schein falls after saying it will not be key supplier to VCA,Pet Partners »

Shares of Henry Schein…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$76.92

-0.45 (-0.58%)

17:51
01/23/19
01/23
17:51
01/23/19
17:51
Hot Stocks
Henry Schein will no longer be key supplier to VCA and Pet Partners »

Mars, Incorporated has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLX

Hologic

$44.40

0.22 (0.50%)

17:50
01/23/19
01/23
17:50
01/23/19
17:50
Hot Stocks
Hologic says FDA grants clearance for Aptima Mycoplasma genitalium assay »

Hologic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.